Skip to content
Screener

Operating Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
$10.69B+246%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
-$23.58M-13.0%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
-$13.42M-11.6%
Alumis Inc. logo
Alumis Inc.ALMS
-$87.08M-8.4%
Upstream Bio, Inc. logo
Upstream Bio, Inc.UPB
-$47.85M-16.2%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
-$54.07M+9.7%

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Cash & equivalents$298.5M+9.9%
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.53B-54.2%
Enterprise value$1.34B-57.2%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The source filing: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 8:55 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001821586-26-000007
(in thousands)Three Months Ended March 31, 2026Three Months Ended March 31, 2025
Trade and other payables(6,173)3,013
Operating lease liabilities(389)(255)
Accrued expenses and other current liabilities7,123(1,556)
Net cash flow used in operating activities(66,286)(38,140)
Cash flow from investing activities
Purchase of short-term marketable debt securities(59,068)(88,548)
Proceeds from maturities of short-term marketable debt securities59,166144,829
Purchase of property and equipment(35)

Item 1. Financial Statements (Unaudited)

FAQ

What is MoonLake Immunotherapeutics's operating cash flow?
MoonLake Immunotherapeutics (MLTX) reported operating cash flow of -$66.29M in Q1 2026.
How has MoonLake Immunotherapeutics's operating cash flow changed year-over-year?
MoonLake Immunotherapeutics's operating cash flow decreased by 73.8% year-over-year, from -$38.14M to -$66.29M.
What is the long-term trend for MoonLake Immunotherapeutics's operating cash flow?
Over 4 years (2021 to 2025), MoonLake Immunotherapeutics's operating cash flow has grown at a 32.9% compound annual growth rate (CAGR), from -$62.9M to -$196.01M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

Ask your AI about MoonLake Immunotherapeutics's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude